Send to:

Choose Destination
See comment in PubMed Commons below
Arch Gerontol Geriatr. 2001 Jun;32(3):275-82.

Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia.

Author information

  • 1Department of Medical Rehabilitation and Geriatrics, Henriettenstiftung, Schwemannstra├če 19, D-30559, Hannover, Germany

Erratum in

  • Arch Gerontol Geriatr. 2010 Jul-Aug;51(1):110.


Oxidative stress and energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD), thus antioxidants with positive effects on glucose metabolism such as thioctic (alpha-lipoic) acid should exert positive effects in these patients. Therefore, 600 mg alpha-lipoic acid was given daily to nine patients with AD and related dementias (receiving a standard treatment with acetylcholinesterase inhibitors) in an open study over an observation period of, on avarage, 337+/-80 days. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (mini-mental state examination: MMSE and AD assessment scale, cognitive subscale: ADAScog). Despite the fact that this study was small and not randomized, this is the first indication that treatment with alpha-lipoic acid might be a successful 'neuroprotective' therapy option for AD and related dementias.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk